Advertisement

The Changing Landscape of Systemic Therapy in the Treatment of Synchronous Metastatic Hormone-sensitive Prostate Cancer

Published:November 13, 2022DOI:https://doi.org/10.1016/j.clgc.2022.11.001

      Abstract

      Introduction

      To describe the changes in systemic treatments (ST) of synchronous metastatic hormone-sensitive prostate cancer (mHSPC) patients in a “real-world” setting and to explore reasons why contemporary standard of care (SOC) was not administrated to the patient.

      Patients and methods

      Since 2014, we prospectively register mHSPCpatients. Patients were grouped in 4 time periods: group 1 (Time period 1, January 2014-July 2015), group 2 after introduction of docetaxel (Time period 2, August 2015-July 2017), group 3 after introduction of abiraterone acetate (Time period 3, August 2017-February 2018) and group 4 after introduction of apalutamide (Time period 4, March 2018-October 2021). For every time period, we evaluated the initiated additional ST. In case patients received treatment that differed from contemporary SOC according to guidelines, reasons for this difference were explored.

      Results

      In total, 243 patients were included. A progressive decline in ADT monotherapy from 85% to 29% over time was observed. The proportion of patients receiving additional STs increased from 34% to 59%. Forty percent of patients were not treated according to contemporary SOC, but this percentage varied strongly per time period (10%, 67%, 53%, and 32% from time period 1 to time period 4 respectively). Reasons for these variations were heterogenous and varied across the 4 time periods. Patients being unfit for treatment and treating physicians failing to consider additional STs were the most prevalent reasons. The proportion of patients unfit for additional ST decreased from 18% to 4% over time.

      Conclusion

      Use of ADT monotherapy declined gradually after the introduction of additional systemic treatments. The proportion of patients unfit for additional ST declined as more treatments became available. Although compliance to SOC increased over time, these real-world data show that adherence to clinical practice guidelines remains suboptimal. Efforts should be made by clinicians to increase the adherence to practice guidelines.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • James ND
        • Spears MR
        • Clarke NW
        • Dearnaley DP
        • De Bono JS
        • Gale J
        • et al.
        Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019).
        Eur Urol. 2015; 67: 1028-1038
        • Pagliarulo V
        • Bracarda S
        • Eisenberger MA
        • et al.
        Contemporary role of androgen deprivation therapy for prostate cancer.
        Eur Urol. 2012; 61: 11-25
        • Nuhn P
        • De Bono JS
        • Fizazi K
        • et al.
        Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology.
        Eur Urol. 2019; 75: 88-99
        • Sweeney CJ
        • Chen Y-H
        • Carducci M
        • et al.
        Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
        N Engl J Med. 2015; 373: 737-746
        • Fizazi K
        • Tran N
        • Fein L
        • et al.
        Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
        N Engl J Med. 2017; 377: 352-360
        • Chi KN
        • Agarwal N
        • Bjartell A
        • et al.
        Apalutamide for metastatic, castration-sensitive prostate cancer.
        N Engl J Med. 2019; 381: 13-24
        • Davis ID
        • Martin AJ
        • Stockler MR
        • et al.
        Enzalutamide with standard first-line therapy in metastatic prostate cancer.
        N Engl J Med. 2019; 381: 121-131
        • Smith MR
        • Saad F
        • Hussain M
        • Sternberg CN
        • Fizazi K
        • Yamada KS
        • et al.
        ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
        J Clin Oncol. 2018; 36 (–TPS383): TPS383
        • Cornford P
        • Van den Bergh R
        • Briers E
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
        European Urology. 2021; 79: 263-282https://doi.org/10.1016/j.eururo.2020.09.046
        • Cornford P
        • Smith EJ
        • MacLennan S
        • et al.
        IMAGINE—IMpact assessment of guidelines implementation and education: the next frontier for harmonising urological practice across Europe by improving adherence to guidelines.
        Eur Urol. 2021; 79: 173-176
        • Freedland SJ
        • Sandin R
        • Sah J
        • et al.
        Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.
        Cancer Med. 2021; 10: 8570-8580
        • Epstein JI
        • Egevad L
        • Amin MB
        • Delahunt B
        • Srigley JR
        • Humphrey PA.
        The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
        Am J Surg Pathol. 2016; 40: 244-252
        • Lambert E
        • Hollebosch S
        • van Praet C
        • et al.
        Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
        Acta Clin Belg. 2021; 77: 897-905
        • Heidenreich A
        • Bastian PJ
        • Bellmunt J
        • et al.
        EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer.
        Eur Urol. 2014; 65: 467-479
        • James ND
        • De Bono JS
        • Spears MR
        • et al.
        Abiraterone for prostate cancer not previously treated with hormone therapy.
        N Engl J Med. 2017; 377: 338-351
        • Armstrong AJ
        • Szmulewitz RZ
        • Petrylak DP
        • et al.
        ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.
        J Clin Oncol. 2019; 37: 2974-2986
        • James ND
        • Sydes MR
        • Clarke NW
        • et al.
        Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
        Lancet. 2016; 387: 1163-1177
        • Lowrance WT
        • Breau RH
        • Chou R
        • et al.
        Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I.
        J Urol. 2021; 205: 14-21
        • Cornford P
        • van den Bergh RCN
        • Briers E
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II—2020 update: treatment of relapsing and metastatic prostate cancer.
        Eur Urol. 2021; 79: 263-282
        • Schaeffer E
        • Srinivas S
        • Antonarakis ES
        • et al.
        NCCN guidelines insights: prostate cancer, version 1.2021.
        J Natl Compr Cancer Netw. 2021; 19: 134-143
        • Hussain M
        • Tangen CM
        • Higano C
        • et al.
        Absolute Prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162).
        J Clin Oncol. 2006; 24: 3984-3990
        • Fizazi K
        • Maldonado X
        • Foulon S
        • et al.
        A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
        J Clin Oncol. 2021; 39 (–5000): 5000
        • Parker CC
        • James ND
        • Brawley CD
        • et al.
        Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
        Lancet. 2018; 392: 2353-2366
        • Buelens S
        • Poelaert F
        • Claeys T
        • et al.
        Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
        BJU Int. 2021; 129: 699-707
        • Ryan CJ
        • Ke X
        • Lafeuille M-H
        • et al.
        Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States.
        J Urol. 2021; 206: 1420-1429
        • Ke X
        • Lafeuille M-H
        • Romdhani H
        • et al.
        Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).
        J Clin Oncol. 2020; 38 (–e19131): e19131
        • Flaig TW
        • Potluri RC
        • Ng Y
        • Todd MB
        • Mehra M
        • Higano CS.
        Disease and treatment characteristics of men diagnosed with metastatic hormone-sensitive prostate cancer in real life: analysis from a commercial claims database.
        Clin Genitourin Cancer. 2017; 15 (e1): 273-279